Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 15/20 | 0.59 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | HRH2 | P25021 | 2/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19940713 | 1.00 | TLR8 (0.59) | TLR8TLR7KCNH2HRH4HRH3 | |
| SCHEMBL22368542 | 0.91 | TLR8 (0.60) | TLR8TLR7KCNH2HRH4HRH3 | |
| SCHEMBL18923203 | 0.90 | TLR8 (0.61) | TLR8TLR7NLRP3 | |
| SCHEMBL18125192 | 0.90 | TLR8 (0.61) | TLR8TLR7NLRP3 | |
| SCHEMBL18109286 | 0.89 | TLR8 (0.74) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL19940722 | 0.89 | TLR8 (0.60) | TLR8TLR7NLRP3 | |
| SCHEMBL19940969 | 0.89 | TLR8 (0.60) | TLR8TLR7NLRP3 | |
| SCHEMBL18109289 | 0.89 | TLR8 (0.74) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109714 | 0.89 | TLR8 (0.75) | TLR8TLR7NLRP3 | |
| SCHEMBL18109715 | 0.89 | TLR8 (0.75) | TLR8TLR7NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4019517-A1 | 2-AMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Shanghai Zhimeng Biopharma, Inc. (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021031960-A1 | 2-AMINOPYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 上海挚盟医药科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-3507288-B1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE DERIVATIES AS TOLL LIKE RECEPTOR MODULATORS | GILEAD SCIENCES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10640499-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20180086755-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640499-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 4271/4885 |
| US-20180086755-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.